Ignite Creation Date:
2025-12-24 @ 7:19 PM
Ignite Modification Date:
2025-12-25 @ 4:58 PM
Study NCT ID:
NCT07150403
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-09-08
First Post:
2025-08-25
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer
Sponsor:
Federation Francophone de Cancerologie Digestive
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-12-31
Start Date Type:
ESTIMATED
Primary Completion Date:
2028-02-28
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-10-31
Completion Date Type:
ESTIMATED
First Submit Date:
2025-08-25
First Submit QC Date:
None
Study First Post Date:
2025-09-02
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-01
Last Update Post Date:
2025-09-08
Last Update Post Date Type:
ESTIMATED